ArticleInfectious diseases and therapy2026
Diagnostic Performance and Clinical Outcomes of Pertussis in Hospitalized Children in Relation to Available Vaccination Status: A Retrospective Cohort Study.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBordetella pertussis infections have resurged globally, posing notable public health challenges, particularly in pediatric populations. Poland remains the only EU country that continues to use the whole-cell pertussis vaccine (wP) in routine immunization. This study evaluated the vaccination status and diagnostic value of available testing modalities in relation to the clinical presentation and management of pertussis in pediatric patients.
methodsA retrospective cohort study of 269 children was conducted between January and December 2024. Patients with B. pertussis infection confirmed by real-time polymerase chain reaction (PCR; PCR-Fluorescence Probing Kit, Sansure, China) and/or serological testing (NovaLisa B. pertussis ELISA, Gold Standard Diagnostic, Germany) were included. Clinical characteristics and vaccination histories of confirmed cases were obtained from electronic medical records and telephone interviews with parents.
resultsPertussis was laboratory-confirmed in 76 of the 269 tested children (28%). PCR accounted for the majority of laboratory-confirmed cases and remained positive in some children during the fifth and sixth week of coughing. The highest proportion of cases was observed in infants under 1 year of age (n = 25, 32.9%). In older age groups, the proportion of cases reached 17% in children aged 1-5 years, 19% in those aged 6-11 years, and 10% in children aged 12-15 years. Adolescents over 15 years of age accounted for only two cases (2.6%). Twelve patients met criteria for severe pertussis (PSS > 5), which occurred in both vaccinated and unvaccinated children. The interval between disease onset and the last vaccine dose ranged from 1 month to 12 years, and a trend toward more pronounced clinical manifestations with longer time since the last booster was observed. No differences in clinical symptoms were found between children vaccinated with wP and acellular (aP) vaccines.
conclusionsThe occurrence of cases several years after vaccination highlights the importance of continued surveillance to strengthen pertussis prevention strategies. Pertussis cases occurring within 5 years of wP vaccination warrant further population-based and molecular studies to evaluate potential factors such as waning immunity or antigenic changes in circulating B. pertussis strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.